Can We Prevent Taste Loss with Talquetamab? TALISMAN Study Brings New Hope | EHA 2026

Talquetamab is an effective GPRC5D-targeted bispecific antibody for multiple myeloma, but taste changes can significantly impact nutrition, quality of life, and a patient’s ability to stay on treatment. At EHA 2026, Dr. Rakesh Popat presents findings from the TALISMAN study, exploring new strategies to prevent and manage these challenging side effects. In thisHealthTree interview, you’ll learn how researchers are objectively measuring taste changes using the Waterless Empirical Taste Test (WETT), what interventions were studied to reduce dysgeusia, and why these findings could improve the treatment experience for patients receiving talquetamab. Whether you’re a patient, caregiver, or healthcare professional, this discussion provides practical insights into supportive care and the future of GPRC5D-directed therapy in multiple myeloma. Subscribe for the latest interviews and research updates from EHA 2026, including breakthroughs in CAR-T therapy, bispecific antibodies, MRD testing, and emerging myeloma treatments. If this video has helped you or a loved one, consider donating to HealthTree. Every donation helps us continue to create free and high-quality blood cancer educational content: https://give.healthtree.org/give/6286... For an organized lesson structure, watch on our site here: https://linktr.ee/HealthTreeUniversity Create a free account to track your progress, bookmark lessons, and keep up-to-date on the latest advancements in treating cancer! Patients have the key to find cures for cancer. Learn more about HealthTree's services here: https://healthtree.org/curehub?utm_so... Educated and empowered patients have better outcomes. We've partnered with hundreds of medical experts and doctors to help you learn more about your disease.